Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC).

Trial Profile

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC).

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Tiotropium bromide (Primary) ; Beclometasone; Salmeterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms TALC
  • Most Recent Events

    • 08 Apr 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 28 Oct 2010 Results published in the New England Journal of Medicine.
    • 17 Sep 2010 Primary endpoint 'Morning peak expiratory flow rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top